Angelman Syndrome

Ionis Advances to Phase 3 Trial for Angelman Syndrome Treatment ION582

9 months ago talkbio0Tagged Angelman Syndrome, Antisense, Biogen, Dosage Forms, ION582, Ionis Pharmaceuticals, neurological conditions, Oligonucleotides, Phase 3 trial, Ultragenyx

Ionis Pharmaceuticals, Angelman syndrome, ION582, Phase 3 trial, antisense oligonucleotides, neurological conditions, rare diseases, Biogen, Ultragenyx Pharmaceutical

Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results

11 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Angelman Syndrome, Biogen, Clinical Trials, Collaboration, Discontinuation (procedure), Early-stage, Ionis, nervous system disorder, readouts

Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.

Ultragenyx’s GTX-102 Shows Promising Results in Mid-Stage Angelman Syndrome Study, Pivotal Study on the Horizon

1 year ago talkbio0Tagged Angelman Syndrome, Antisense Oligonucleotides, Behavioral Improvement, Cognitive Improvement, Gross Motor Improvement, GTX-102, mid-stage study, Sleep Improvement, Ultragenyx

Ultragenyx, GTX-102, Angelman Syndrome, Mid-Stage Study, Pivotal Study, Antisense Oligonucleotide, Cognitive Improvement, Behavioral Improvement, Sleep Improvement, Gross Motor Improvement